Hyperbaric Novabupi® in Spinal Anesthesia in Lower Limbs Vascular Surgery

Non-inferiority Study of Hyperbaric Novabupi® (Bupivacaine S75: R25) Compared to Hyperbaric Neocaine® (Bupivacaine S50: R50) in Spinal Anesthesia in Lower Limbs Vascular Surgery

This is a multicenter, randomized, double-blind, active-controlled study to evaluate the non-inferiority of hyperbaric Novabupi® versus hyperbaric Neocaine® in spinal anesthesia in lower limbs vascular surgery.

The schedule consists of four visits: screening (visit 1); pre-anesthetic evaluation and randomization (visit 2); treatment (visit 3) and discharge from study (visit 4).

Study Overview

• Status: Recruiting
• Conditions: Spinal Anesthesia; Vascular Surgery
• Intervention / Treatment: Drug: bupivacaine S75:R25 plus 8% glucose; Drug: bupivacaine S50:R50 plus 8% glucose

• Study Type: Interventional
• Enrollment (Anticipated): 120
• Phase: Phase 3

Contacts and Locations

Study Locations

• Brazil
  • Maranhão
    • São Luís, Maranhão, Brazil, 65020-600
      • Recruiting
      • CEPEC
      • Contact: Joilma Tobias, Nurse; Phone Number: 55 98 2109-1293; Email: joilma.tobias@huufma.br
      • Contact: Renata Assis, Pharmacy; Phone Number: 55 98 2109-1294; Email: renata.assis@huufma.br

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Provision of written informed consent
• Both sexes
• Age between 18 and 80 years, inclusive
• ASA category I or II
• Indication of spinal anesthesia for varicose vein surgery in lower limbs with a maximum duration of 3 hours.

Exclusion Criteria:

• Contraindications to spinal anesthesia
• Hypersensitivity or intolerance to local anesthetics or to the components of formula
• Use of any anticoagulant, regardless of type until 60 days before entering the study
• Spinal cord injuries, peripheral neuropathies or any other neurological conditions leading to sensory and / or motor disorders
• Dementia, mental retardation and other major cognitive changes
• Obesity with body mass index (BMI) > 30 or difficulty in performing the puncture
• Anatomical difficulty in the spine in the opinion of the Investigator that can make puncture difficult
• Any previous surgical intervention of the spine
• Tattoo at the puncture site
• Participants with a history of alcohol or illicit drug abuse, as defined by Diagnostic and Statistical Manual of Mental Disorders, 5th edition
• Pernicious anemia
• History of severe anaphylactic reactions or Steven-Johnson disease

• Changes in safety exams (applicable at the time of randomization):

  • International Normalized Ratio ≥ 1.4
  • Hemoglobin < 10 g / dL
  • Platelet count <100,000 / mm3
  • Glycemia> 200 mg / dL
  • Bradyarrhythmias: heart block with clinical repercussion in the investigator's opinion
  • Maximum of eight ventricular extrasystoles per minute, evident on the ECG
• Pregnancy or lactation
• Any other condition that, in the opinion of the Investigator, may lead to an increased risk for the participant.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Hyperbaric Novabupi® 0.5% (bupivacaine S75:R25 + 8% glucose)	Drug: bupivacaine S75:R25 plus 8% glucose; Spinal anesthesia, 20 mg
ACTIVE_COMPARATOR: Hyperbaric Neocaine® 0.5% (bupivacaine S50:R50 + 8% glucose)	Drug: bupivacaine S50:R50 plus 8% glucose; Spinal anesthesia, 20 mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison between arms from latency to T10 dermatome sensitive block	Time elapsed between the withdrawal of the needle at the end of the injection of the local anesthetic and the absence of response to sensorial stimuli in the region corresponding to the T10 dermatome	20 minutes
Comparison between arms from the duration of the sensory block	Time elapsed between the withdrawal of the needle at the end of the local anesthetic injection and the presence of positive sensitivity by needle stimulation in the L5 dermatome	24 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison between arms from the degree of motor blockage when blocking T10 sensitive	The motor block will be evaluated by the modified Bromage scale. The degree of motor block will be assessed when the sensory block reaches T10. The motor block will be evaluated every 5 minutes from the end of the anesthetic injection (time 0) through the modified Bromage scale: 0 = without motor block,; 1 = blocked hip,; 2 = blocked hip and knee,; 3 = blocked hip, knee and ankle. Will be recorded: the degree of motor blockage when the sensory block reaches T10,; the time to reach the maximum block,; time for full recovery (Bromage score 0).	20 minutes
Comparison between arms from the duration of the motor block	Duration of motor block will be considered as the time interval between needle withdrawal after puncture and return to score 0 on the modified Bromage scale. Time will be recorded to reach grade 3 motor block and at the end of surgery. During anesthesia recovery, evaluations will be performed every 15 minutes	24 hours
Comparison between arms from the highest level of sensory block		3 hours
Comparison between arms from the time to reach the highest level of sensory block		1 hour
Comparison between arms from the time for the 4-segment regression of the sensory block	The height of the sensitive block will be evaluated every 5 minutes until the maximum level is reached. From this point, the height of the block will be evaluated every 10 minutes until the regression of 4 levels	3 hours
Comparison between arms of respiratory and cardiovascular safety	Evidenced by the incidence, severity and causality of clinically significant SpO2 changes. Every 5 minutes SpO2 will be recorded until completing 60 minutes, every 10 minutes until completing 120 minutes, every 20 minutes until 12 hours.	12 hours
Comparison between arms of cardiovascular safety	Evidenced by the incidence, severity and causality of clinically significant changes in blood pressure measured automatically by cardiac monitoring. Every 5 minutes blood pressure will be recorded until completing 60 minutes, every 10 minutes until completing 120 minutes, every 20 minutes until completing 180 minutes and every 30 minutes until complete recovery of the motor function.	24 hours
Comparison between arms of cardiovascular safety	Evidenced by the incidence, severity and causality of clinically significant changes in heart rate measured automatically by cardiac monitoring. Every 5 minutes heart rate will be recorded until completing 60 minutes, every 10 minutes until completing 120 minutes, every 20 minutes until completing 180 minutes and every 30 minutes until complete recovery of the motor function	12 hours
Comparison between arms from the percentage of motor and sensory block failure	After the needle has been withdrawn, the anesthetic should be installed for up to 20 minutes. If no sensory and / or motor blockage is observed after this period, the Investigator will indicate that there was an anesthetic failure that should be classified as: A. total block failure (absence of anesthesia in sensory and motor aspects with preserved sensitivity of the perineal region) B. partial failure (when any area below the T10 dermatome shows signs of analgesia or motor block, but surgery can not be performed, requiring intense sedation or general anesthesia). In case of failure, the participant will be immediately discontinued from the study and the surgery will normally proceed with anesthetic procedure at the discretion of the Investigator. Anesthesia failure should be reported as an adverse event.	20 minutes
Comparison between arms from the occurrence of adverse events	Adverse event information will be collected from all participants on all visits	7 days

Collaborators and Investigators

• Sponsor: Cristália Produtos Químicos Farmacêuticos Ltda.

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 1, 2022
• Primary Completion (ANTICIPATED): April 30, 2023
• Study Completion (ANTICIPATED): November 30, 2023

Study Registration Dates

• First Submitted: March 11, 2019
• First Submitted That Met QC Criteria: March 18, 2019
• First Posted (ACTUAL): March 21, 2019

Study Record Updates

• Last Update Posted (ACTUAL): February 8, 2023
• Last Update Submitted That Met QC Criteria: February 7, 2023
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Anesthetics, Local; Bupivacaine
• Other Study ID Numbers: CRT090

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No